Literature DB >> 10485908

Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux.

Z L Harris1, A P Durley, T K Man, J D Gitlin.   

Abstract

Aceruloplasminemia is an autosomal recessive disorder of iron metabolism. Affected individuals evidence iron accumulation in tissue parenchyma in association with absent serum ceruloplasmin. Genetic studies of such patients reveal inherited mutations in the ceruloplasmin gene. To elucidate the role of ceruloplasmin in iron homeostasis, we created an animal model of aceruloplasminemia by disrupting the murine ceruloplasmin (Cp) gene. Although normal at birth, Cp(-/-) mice demonstrate progressive accumulation of iron such that by one year of age all animals have a prominent elevation in serum ferritin and a 3- to 6-fold increase in the iron content of the liver and spleen. Histological analysis of affected tissues in these mice shows abundant iron stores within reticuloendothelial cells and hepatocytes. Ferrokinetic studies in Cp(+/+) and Cp(-/-) mice reveal equivalent rates of iron absorption and plasma iron turnover, suggesting that iron accumulation results from altered compartmentalization within the iron cycle. Consistent with this concept, Cp(-/-) mice showed no abnormalities in cellular iron uptake but a striking impairment in the movement of iron out of reticuloendothelial cells and hepatocytes. Our findings reveal an essential physiologic role for ceruloplasmin in determining the rate of iron efflux from cells with mobilizable iron stores.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485908      PMCID: PMC17965          DOI: 10.1073/pnas.96.19.10812

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Iron is hot: an update on the pathophysiology of hemochromatosis.

Authors:  N C Andrews; J E Levy
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

Review 2.  Regulation of transition metal transport across the yeast plasma membrane.

Authors:  D Radisky; J Kaplan
Journal:  J Biol Chem       Date:  1999-02-19       Impact factor: 5.157

Review 3.  Function and regulation of transferrin and ferritin.

Authors:  P Ponka; C Beaumont; D R Richardson
Journal:  Semin Hematol       Date:  1998-01       Impact factor: 3.851

4.  HFE gene knockout produces mouse model of hereditary hemochromatosis.

Authors:  X Y Zhou; S Tomatsu; R E Fleming; S Parkkila; A Waheed; J Jiang; Y Fei; E M Brunt; D A Ruddy; C E Prass; R C Schatzman; R O'Neill; R S Britton; B R Bacon; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

5.  Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse.

Authors:  C D Vulpe; Y M Kuo; T L Murphy; L Cowley; C Askwith; N Libina; J Gitschier; G J Anderson
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

Review 6.  Aceruloplasminemia.

Authors:  J D Gitlin
Journal:  Pediatr Res       Date:  1998-09       Impact factor: 3.756

7.  Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism.

Authors:  Z K Attieh; C K Mukhopadhyay; V Seshadri; N A Tripoulas; P L Fox
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

8.  Expression of SFT (stimulator of Fe transport) is enhanced by iron chelation in HeLa cells and by hemochromatosis in liver.

Authors:  J Yu; Z K Yu; M Wessling-Resnick
Journal:  J Biol Chem       Date:  1998-12-25       Impact factor: 5.157

9.  Ran-2, a glial lineage marker, is a GPI-anchored form of ceruloplasmin.

Authors:  J L Salzer; L Lovejoy; M C Linder; C Rosen
Journal:  J Neurosci Res       Date:  1998-10-15       Impact factor: 4.164

Review 10.  New knowledge of genetic pathogenesis of hemochromatosis and Wilson's disease.

Authors:  B R Bacon; M L Schilsky
Journal:  Adv Intern Med       Date:  1999
View more
  142 in total

1.  Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding.

Authors:  R E Fleming; W S Sly
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Mining copper transport genes.

Authors:  N C Andrews
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

Review 3.  Molecular pathogenesis of iron overload.

Authors:  D Trinder; C Fox; G Vautier; J K Olynyk
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 4.  Animal models of age related macular degeneration.

Authors:  Mark E Pennesi; Martha Neuringer; Robert J Courtney
Journal:  Mol Aspects Med       Date:  2012-06-15

Review 5.  Murine mutants in the study of systemic iron metabolism and its disorders: an update on recent advances.

Authors:  Thomas B Bartnikas; Mark D Fleming; Paul J Schmidt
Journal:  Biochim Biophys Acta       Date:  2012-01-28

6.  Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice.

Authors:  G Nicolas; M Bennoun; I Devaux; C Beaumont; B Grandchamp; A Kahn; S Vaulont
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

7.  Extrapyramidal and cerebellar movement disorder in association with heterozygous ceruloplasmin gene mutation.

Authors:  Jens Kuhn; Hiroaki Miyajima; Yoshitomo Takahashi; Bernhard Kunath; Ursula Hartmann-Klosterkoetter; Déirdre Cooper-Mahkorn; Mark Schaefer; Heiko Bewermeyer
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

8.  Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

Authors:  R Mariani; C Arosio; S Pelucchi; M Grisoli; A Piga; P Trombini; A Piperno
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 9.  Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?

Authors:  Duygu Dee Harrison-Findik
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

Review 10.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.